Immunologic response to highly active antiretroviral therapy and mortality reduction in a cohort of human immunodeficiency virus-positive persons in mozambique

American Journal of Tropical Medicine and Hygiene

Volumn 83, Issue 5, 2010, Pages 1128-1132

  Palombi, Leonardo ^a   Dorrucci, Maria ^b   Zimba, Ines ^c   Scarcella, Paola ^a   Mancinelli, Sandro ^a   Buonomo, Ersilia ^a   Guidotti, Giovanni ^b   Marazzi, Maria C ^d   Rezza, Giovanni ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c Malnutrition Program Coordination   (Mozambique)

^d LUMSA UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOZAMBIQUE; PREDICTIVE VALUE; PROGNOSIS; RISK REDUCTION; SURVIVAL RATE; CD4+ T LYMPHOCYTE; DRUG ADMINISTRATION; IMMUNOLOGY; MIDDLE AGED;

HUMAN IMMUNODEFICIENCY VIRUS;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MOZAMBIQUE; YOUNG ADULT;

EID: 79952057272     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2010.09-0705     Document Type: Article

References (17)

1. UNAIDS/WHO. AIDS Epidemic Update 2008. Available at: http://data.unaids. org/pub/GlobalReport/2008/jc1510-2008-global-report-pp29-62-en.pdf.
2. World Health Organization, Towards Universal Access: Scaling Up Priority HIV/AIDS Intervention in the Health Sector: Progress Report; April 2007. Geneva: World Health Organization. Available at: http://www.who.int/hiv/mediacentre/ univeral-access-progress-report-en.pdf.
3. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R, 2008. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22: 1897-1908.
4. Bekker LG, Myer L, Orrel C, Lawn S, Wood R, 2006. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J 96: 315-320.
5. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, Reuter H, Ntwana N, Goemaere E, 2004. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18: 887-895. (Pubitemid 38553709)
6. Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, Peter PF, Gaolathe T, Mujugira A, Busang L, Vanderwarker C, Cardiello P, Johnson O, Thior I, Mazonde P, Moffat H, Essex M, Marlink R, 2005. Initial response to highly active antiretroviral therapy in HIV-1 C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 40: 336-342.
7. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) Groups, 2006. Mortality of HIV-1 infected patients in the first year of antiretroviral therapy; comparison between low-income and high-income countries. Lancet 367: 817-824.
8. Ivers LC, Kendrick D, Doucette K, 2005. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 41: 217-224. (Pubitemid 40962502)
9. Lawn SD, Myer L, Harling G, Orrel C, Bekker LG, Wood R, 2006. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South-Africa: implications for program evaluation. Clin Infect Dis 43: 770-776. (Pubitemid 44330743)
10. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, Abo Y, Salamon R, Bissagnene E, Seyler C, Eholié S, Anglaret X, 2007. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in Wet Africa. AIDS 21: 2483-2491. (Pubitemid 350145180)
11. Marazzi MC, Guidotti G, Liotta G, Palombi L, 2005. DREAM: An Integrated Faith-Based Initiative to treat HIV/AIDS in Mozambique, Case Study. Perspectives and Practice in Antiretroviral Ttreatment. Sant' Egido Mozambique and Geneva: World Health Organization.
12. Marazzi MC, Germano P, Liotta G, Guidotti G, Loureiro S, da Cruz Gomes A, Valls Blazques MC, Narciso P, Perno CF, Mancinelli S, Palombi L, 2006. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med 7: 338-344. (Pubitemid 43805695)
13. Cleveland WS, 1979. Robust locally-weighted regression and smoothing scatterplots. JASA 74: 829-836.
14. Rosen S, Fox MP, Gill CJ, 2007. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4: e298.
15. Etard JF, Ndiaye I, Thierry-Mieg M, Guèye NF, Guèye PM, Lanièce I, Dieng AB, Diouf A, Laurent C, Mboup S, Sow PS, Delaporte E, 2006. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20: 1181-1189. (Pubitemid 43786107)
16. De Cock KM, Gilks CF, Lo YR, Guerma T, 2009. Can antiretroviral therapy eliminate HIV transmission? Lancet 373: 7-9.
17. Chêne G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME; Antiretroviral Therapy Cohort Collaboration, 2003. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 362: 679-686.